Seres Therapeutics Inc. [NASDAQ: MCRB] plunged by -$0.66 during the normal trading session on Friday and reaching a high of $25.7577 during the day while it closed the day at $24.12. The company report on November 19, 2020 that Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences.
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced that management will participate in two upcoming investor conferences:.
Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020 where management will participate in 1×1 meetings. A fireside chat held with Seres management will be made available on the News and Events section of the Company’s website on November 23, 2020.
Seres Therapeutics Inc. stock has also loss -0.90% of its value over the past 7 days. However, MCRB stock has declined by -8.18% in the 3 months of the year. Over the past six months meanwhile, it has gained 396.30% and gained 599.13% year-on date.
The market cap for MCRB stock reached $2.26 billion, with 83.53 million shares outstanding and 82.80 million shares in the current float. Compared to the average trading volume of 768.28K shares, MCRB reached a trading volume of 5053749 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Seres Therapeutics Inc. [MCRB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MCRB shares is $37.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MCRB stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Chardan Capital Markets have made an estimate for Seres Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on September 18, 2020. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on August 18, 2020, representing the official price target for Seres Therapeutics Inc. stock. Previously, the target price had yet another raise from $4 to $29, while Jefferies kept a Buy rating on MCRB stock. On August 11, 2020, analysts increased their price target for MCRB shares from 8 to 41.
The Average True Range (ATR) for Seres Therapeutics Inc. is set at 1.99, with the Price to Sales ratio for MCRB stock in the period of the last 12 months amounting to 97.04. The Price to Book ratio for the last quarter was 10.72, with the Price to Cash per share for the same quarter was set at 3.18.
MCRB stock trade performance evaluation
Seres Therapeutics Inc. [MCRB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.90. With this latest performance, MCRB shares dropped by -30.15% in over the last four-week period, additionally plugging by 396.30% over the last 6 months – not to mention a rise of 460.93% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MCRB stock in for the last two-week period is set at 37.80, with the RSI for the last a single of trading hit 36.06, and the three-weeks RSI is set at 40.67 for Seres Therapeutics Inc. [MCRB]. The present Moving Average for the last 50 days of trading for this stock 30.02, while it was recorded at 24.73 for the last single week of trading, and 15.36 for the last 200 days.
Seres Therapeutics Inc. [MCRB]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Seres Therapeutics Inc. [MCRB] shares currently have an operating margin of -203.98. Seres Therapeutics Inc.’s Net Margin is presently recorded at -203.68.
Reflecting on the efficiency of the workforce at the company, Seres Therapeutics Inc. [MCRB] managed to generate an average of -$650,731 per employee. Receivables Turnover for the company is 38.66 with a Total Asset Turnover recorded at a value of 0.27.Seres Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.70 and a Current Ratio set at 6.70.
Earnings per share (EPS) analysis for Seres Therapeutics Inc. [MCRB] stock
With the latest financial reports released by the company, Seres Therapeutics Inc. posted -0.25/share EPS, while the average EPS was predicted by analysts to be reported at -0.28/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 10.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MCRB.
Seres Therapeutics Inc. [MCRB]: Insider Ownership positions
There are presently around $2,077 million, or 88.60% of MCRB stock, in the hands of institutional investors. The top three institutional holders of MCRB stocks are: FLAGSHIP PIONEERING INC. with ownership of 21,571,764, which is approximately 0% of the company’s market cap and around 9.26% of the total institutional ownership; ARK INVESTMENT MANAGEMENT LLC, holding 12,293,033 shares of the stock with an approximate value of $296.51 million in MCRB stocks shares; and FMR LLC, currently with $258.5 million in MCRB stock with ownership of nearly 86.647% of the company’s market capitalization.
Positions in Seres Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 76 institutional holders increased their position in Seres Therapeutics Inc. [NASDAQ:MCRB] by around 21,788,926 shares. Additionally, 48 investors decreased positions by around 7,899,964 shares, while 7 investors held positions by with 56,419,446 shares. The mentioned changes placed institutional holdings at 86,108,336 shares, according to the latest SEC report filing. MCRB stock had 37 new institutional investments in for a total of 8,776,274 shares, while 17 institutional investors sold positions of 521,819 shares during the same period.